Publication | Closed Access

Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study

InflammationMolecular BiomarkersHematological MalignancyOncologyRuxolitinib TreatmentMedicinePharmacotherapyPhase 2PharmacologyMyeloid Neoplasia